Literature DB >> 18984890

Anaplastic large-cell lymphoma in women with breast implants.

Daphne de Jong1, Wies L E Vasmel, Jan Paul de Boer, Gideon Verhave, Ellis Barbé, Mariel K Casparie, Flora E van Leeuwen.   

Abstract

CONTEXT: Recently, we identified 2 patients with anaplastic large T-cell lymphoma (ALCL) negative for tyrosine kinase anaplastic lymphoma kinase (ALK-negative) in the fibrous capsule of silicone breast prostheses, placed for cosmetic reasons. Similar cases have been reported in the literature. Although an increased risk of ALCL in patients with breast prostheses has been speculated, no studies have been conducted so far.
OBJECTIVE: To determine whether ALCL risk is associated with breast prostheses.
DESIGN: A search for all patients with lymphoma in the breast diagnosed in The Netherlands between 1990 and 2006 was performed through the population-based nationwide pathology database. Subsequently, we performed an individually matched case-control study. Conditional logistic regression analysis was performed to estimate the relative risk of ALCL associated with breast prostheses. SETTING AND PATIENTS: Eleven patients with breast ALCL were identified in the registry. For each case patient with ALCL in the breast, we selected 1 to 5 controls with other lymphomas in the breast, matched on age and year of diagnosis. For all cases and controls (n = 35), pathological and clinical information was obtained with special emphasis on the presence of a breast prosthesis. MAIN OUTCOME MEASURE: Association between breast implants and ALCL of the breast.
RESULTS: The 11 patients with ALCL of the breast were diagnosed between 1994 and 2006 at a median age of 40 years (range, 24-68 years). In 5 of these patients, bilateral silicone breast prostheses had been placed 1 to 23 years before diagnosis. All received prostheses for cosmetic reasons. Lymphoma classes of 35 eligible control patients were 12 diffuse large B-cell lymphomas, including 1 T-cell rich B-cell lymphoma; 5 Burkitt lymphomas; 10 mucosa-associated lymphoid tissue-type lymphoma; 3 follicular lymphomas; 3 peripheral T-cell lymphomas; and 2 indolent B-cell lymphomas, unclassified. One of 35 control patients had a breast implant placed before diagnosis of lymphoma. The odds ratio for ALCL associated with breast prostheses was 18.2 (95% confidence interval, 2.1-156.8).
CONCLUSIONS: These preliminary findings suggest an association between silicone breast prostheses and ALCL, although the absolute risk is exceedingly low due to the rare occurrence of ALCL of the breast (11 cases in The Netherlands in 17 years). These findings require confirmation in other studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984890     DOI: 10.1001/jama.2008.585

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  72 in total

Review 1.  Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management.

Authors:  Tessa L St Cyr; Barbara A Pockaj; Donald W Northfelt; Fiona E Craig; Mark W Clemens; Raman C Mahabir
Journal:  Plast Surg (Oakv)       Date:  2020-05-21       Impact factor: 0.947

Review 2.  Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity.

Authors:  Philip A Thompson; Stephen Lade; Howard Webster; Gail Ryan; H Miles Prince
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

3.  Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity.

Authors:  Melissa G Lechner; Stephen Lade; Daniel J Liebertz; H Miles Prince; Garry S Brody; Howard R Webster; Alan L Epstein
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

Review 4.  Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis.

Authors:  Philip A Thompson; H Miles Prince
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

5.  PIP breast implants: rupture rate and correlation with breast cancer.

Authors:  M Moschetta; M Telegrafo; I Cornacchia; L Vincenti; V Ranieri; A Cirili; L Rella; A A Stabile Ianora; G Angelelli
Journal:  G Chir       Date:  2014 Nov-Dec

Review 6.  Evolution and update on current devices for prosthetic breast reconstruction.

Authors:  Kristina O'Shaughnessy
Journal:  Gland Surg       Date:  2015-04

7.  Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.

Authors:  Roberto N Miranda; Tariq N Aladily; H Miles Prince; Rashmi Kanagal-Shamanna; Daphne de Jong; Luis E Fayad; Mitual B Amin; Nisreen Haideri; Govind Bhagat; Glen S Brooks; David A Shifrin; Dennis P O'Malley; Chan Y Cheah; Carlos E Bacchi; Gabriela Gualco; Shiyong Li; John A Keech; Ephram P Hochberg; Matthew J Carty; Summer E Hanson; Eid Mustafa; Steven Sanchez; John T Manning; Zijun Y Xu-Monette; Alonso R Miranda; Patricia Fox; Roland L Bassett; Jorge J Castillo; Brady E Beltran; Jan Paul de Boer; Zaher Chakhachiro; Dongjiu Ye; Douglas Clark; Ken H Young; L Jeffrey Medeiros
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 8.  Breast implant-associated ALCL: a unique entity in the spectrum of CD30+ lymphoproliferative disorders.

Authors:  Sara K Story; Michael K Schowalter; Larisa J Geskin
Journal:  Oncologist       Date:  2013-02-21

9.  Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls.

Authors:  Evan A Farkash; Judith A Ferry; Nancy Lee Harris; Ephraim P Hochberg; Ronald W Takvorian; Dan S Zuckerman; Aliyah R Sohani
Journal:  J Hematop       Date:  2009-08-20       Impact factor: 0.196

10.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-03       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.